Latest Advances in Lung Cancer Research

FDA approves Opdivo for early-stage NSCLC. This immunotherapy can be used before and after surgery, potentially improving outcomes for patients with resectable lung cancer.

Immunotherapy and chemotherapy before surgery show promise for stage 3 NSCLC patients, with 77% achieving two-year progression-free survival.

AstraZeneca’s Imfinzi shows promise in treating aggressive small cell lung cancer, potentially offering a new, more effective treatment option for this hard-to-treat disease.

Study indicates advanced lung cancer patients may stop immunotherapy after 2 years without impacting survival, requiring further research for confirmation.

A recent multicenter study published in The Lancet highlights the promising efficacy of immunotherapy in advanced lung cancer patients.

A study conducted by Penn Medicine researchers has shown that some patients with advanced lung cancer may benefit from a shorter duration of immunotherapy treatment, a type of cancer treatment that helps the immune system fight cancer cells.

New treatments like immunotherapy and targeted therapy are improving post-surgery outcomes for lung cancer, with research ongoing to optimize these methods.

New report shows that many of the tumors with low PD-L1 have developed genetic strategies that avoid immunotherapies.

Pre-surgical immunotherapy along with post-surgical immunotherapy significantly improved survival compared to chemotherapy alone for patients with operable non-small cell lung cancer.

Merck’s Keytruda reduces early-stage lung cancer recurrence by 24% post-surgery, with plans for FDA approval submission, and shows a favorable safety profile.

The FDA rapidly approved Bristol Myers Squibb’s Opdivo for early-stage NSCLC, marking a major advancement in pre-surgical cancer treatment.